What is he best known for?
The fields of study he is best known for:
- Immune system
- Cytokine
- Gene
Immunology, Primary biliary cirrhosis, Autoimmunity, IL-2 receptor and CD8 are his primary areas of study.
The Immunology study combines topics in areas such as Molecular biology and Cytotoxic T cell.
Zhe-Xiong Lian combines subjects such as Hepatic fibrosis, Hepatic stellate cell, Natural killer T cell, Natural killer cell and Proinflammatory cytokine with his study of Primary biliary cirrhosis.
His Autoimmunity study combines topics in areas such as Myasthenia gravis, Molecular mimicry, Rheumatoid arthritis, Regulatory T cell and Multiple sclerosis.
Zhe-Xiong Lian focuses mostly in the field of IL-2 receptor, narrowing it down to matters related to Interleukin 2 and, in some cases, Interleukin 17, Interleukin 10, Spleen and Immunopathology.
In CD8, Zhe-Xiong Lian works on issues like T cell, which are connected to Autoimmune hepatitis, FOXP3, Hepatitis and CTL*.
His most cited work include:
- Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. (248 citations)
- Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis (242 citations)
- Anti-Mitochondrial Antibodies and Primary Biliary Cirrhosis in TGF-β Receptor II Dominant-Negative Mice (199 citations)
What are the main themes of his work throughout his whole career to date?
Zhe-Xiong Lian focuses on Immunology, Primary biliary cirrhosis, Molecular biology, T cell and Autoimmunity.
His work in Immunology is not limited to one particular discipline; it also encompasses Cytotoxic T cell.
His biological study spans a wide range of topics, including Natural killer T cell, Autoantibody, Antibody and Endocrinology.
His work deals with themes such as In vitro, CD11c, MHC class I, Major histocompatibility complex and Epitope, which intersect with Molecular biology.
His work in the fields of MHC class II overlaps with other areas such as Primary sclerosing cholangitis.
His Autoimmunity research also works with subjects such as
- Proinflammatory cytokine which connect with Interleukin 6 and Colitis,
- Tumor necrosis factor alpha that intertwine with fields like Adoptive cell transfer.
He most often published in these fields:
- Immunology (86.08%)
- Primary biliary cirrhosis (46.84%)
- Molecular biology (25.32%)
What were the highlights of his more recent work (between 2010-2013)?
- Immunology (86.08%)
- Primary biliary cirrhosis (46.84%)
- Internal medicine (20.25%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Immunology, Primary biliary cirrhosis, Internal medicine, Receptor and Inflammation.
His Immunology research is multidisciplinary, incorporating perspectives in Donor lymphocyte infusion, Subcutaneous injection and Transplantation.
His Internal medicine research incorporates themes from Gastroenterology, Cytotoxic T cell and Endocrinology.
The concepts of his Endocrinology study are interwoven with issues in Autoantibody, Antibody, Rituximab, Immunophenotyping and Hepatology.
His study in Receptor is interdisciplinary in nature, drawing from both Interleukin, Interleukin 17, Cytokine and Pathogenesis.
He interconnects Cancer research, Colitis, Immunopathology, Transforming growth factor and Interleukin 12 in the investigation of issues within Inflammation.
Between 2010 and 2013, his most popular works were:
- Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. (106 citations)
- Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. (106 citations)
- Deletion of interleukin (IL)‐12p35 induces liver fibrosis in dominant‐negative TGFβ receptor type II mice (72 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
